Urinary tract infections in kidney transplant patients admitted to hospital: A real-life experience

Table 1 Characteristics of enrolled patients

Characteristics		Value
Age in years, median (IQR)		56 (37-72)
Sex, n (%)
	Male	16 (52)
	Female	15 (48)
Comorbidities, n (%)
	Hypertension	27 (87)
	Obesity	15 (48)
	Type II diabetes mellitus	4 (13)
	Cardiovascular disease	2 (6)
	Hypothyroidism	2 (6)
	COPD	1 (3)
Type of transplant, n (%)
	Kidney transplant	30 (97)
	Kidney - pancreas transplant	1 (3)
Indication for the transplant, n (%)
	Chronic renal failure	13 (42)
	ADPKD	8 (27)
	Systemic lupus erythematosus	3 (10)
	IgA nephropathy	2 (6)
	VUR	2 (6)
	Hypertensive nephropathy	2 (6)
	Diabetic nephropathy	1 (3)
Induction immunosuppressive therapy, n (%)
	Basiliximab + methylprednisolone	31 (100)
Immunosuppressive therapy at diagnosis, n (%)
	Tacrolimus – mycophenolate - steroids	16 (52)
	Tacrolimus – everolimus - steroids	3 (10)
	Cyclosporine – mycophenolate - steroids	1 (3)
	Cyclosporine – everolimus - steroids	1 (3)
	Tacrolimus - steroids	6 (20)
	Cyclosporine - steroids	4 (12)
Time from transplant in months, mean (IQR)		49 (2-312)
	TOE	T1
WBC as cell/µL, median (IQR)	14220 (4380-21740)	9885 (3760-15920)
PLT as cell/µL, median (IQR)	379000 (68000-512000)	274000 (83000-492000)
Creatinine in mg/dL, median (IQR)	2.2 (1.5-4.7)	1.9 (1.4-3.5)
Bilirubin in mg/dL, median (IQR)	1.4 (0.9-2.9)	1.1 (0.7-2.3)
CRP in mg/L median (IQR)	55 (9-130)	29 (4-68)

ADPKD: Autosomal dominant polycystic kidney disease; COPD: Chronic obstructive pulmonary disease; CRP: C-reactive protein; IQR: Interquartile range; PLT: Platelets; TOE: Time of enrollment, T1 time of 4 days post-therapy; VUR: Vesicoureteral reflux.